Current status and new developments with galantamine in the treatment of Alzheimer’s disease

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.12, 2001-12, pp. : 2027-2049

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimers Disease

By Wilcock G.

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

By Marco-Contelles José Rodríguez Carolina García Antonio G

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 5, 2005-05 ,pp. : 575-587

Informa Healthcare

Access to resources Recommend Favorite

Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimers Disease with Cerebrovascular Disease

By Small G.

CNS Drugs, Vol. 17, Iss. 12, 2003-01 ,pp. : 905-914

Adis International

Access to resources Recommend Favorite

The pharmacology of donepezil: a new treatment for Alzheimer’s disease

By Wilkinson D.G.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 121-135

Informa Healthcare

Access to resources Recommend Favorite

Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimers Disease in the Health Care Systems of Different Countries

By Jaime Caro Maribel Salas

Drugs & Aging, Vol. 21, Iss. 10, 2004-01 ,pp. : 677-686

Adis International

Access to resources Recommend Favorite